Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms AVERT
- 15 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2019.
- 15 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Aug 2019.
- 04 Mar 2014 New trial record